Trial results for the extension study NCT03769168 investigating subcutaneous secukinumab in patients with Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) were posted on ClinicalTrials.gov on 2025-05-23. The study reported that participants receiving secukinumab achieved a 100% Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 response in multiple dose groups.
Background
The study, titled "An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)," was an optional open-label, roll-over extension study. It aimed to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes, specifically Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).
Trial design
The extension study (NCT03769168) was a Phase 3 trial that enrolled 55 participants. The study investigated subcutaneous secukinumab in patients diagnosed with Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis. It was designed as an open-label, roll-over extension study.
Key results
The trial reported multiple measurements for the "Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response" across different dose groups:
- For participants in Group 1 (Secukinumab 75 mg), the JIA ACR 30 response was consistently reported as 100%.
- For participants in Group 2 (Secukinumab 150 mg), the JIA ACR 30 response was reported as 100% in several instances, and 96.9% in another.
- For the Total Secukinumab Dose group, the JIA ACR 30 response was reported as 100% in several instances, and 98.9% in another.
What this means
The high rates of Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 response observed in this extension study suggest that secukinumab may offer significant clinical benefit for patients with Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis. The consistent and high response rates across both 75 mg and 150 mg dose groups indicate potential efficacy for secukinumab in managing these challenging conditions in a pediatric population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03769168, titled "An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)," were posted on 2025-05-23 on clinicaltrials.gov.